Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study

Fig. 2

Anti-Ro52 positivity predicts decline in vital capacity. Lung function, expressed as percentage of predicted vital capacity (%pVC) over time, declines in anti-Ro52 seropositive systemic sclerosis patients with interstitial lung disease (-2.41%pVC/year; 95% CI: -4.28 – -0.54; p = 0.013). Prediction model using mixed model regression equation including anti-Ro52, anti-Scl-70, disease subtype, and immunomodulator use, with time-interaction terms, and sex; 95% confidence intervals indicated by shaded ribbons

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us